40 Papers
158 Citations
Soulé Jc is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Placebo & Medicine. The author has an hindex of 19, co-authored 40 publications. Previous affiliations of Soulé Jc include University of Paris.
Chat about Author
Papers
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy
Jean-Frederic Colombel,Nicolas Ferrari,Hervé Debuysere,Philippe Marteau,Jean Pierre Gendre,Bruno Bonaz,Soulé Jc,Robert Modigliani,Yvan Touze,Pascale Catala,Christian Libersa,Franck Broly +11 more
TL;DR: Twenty-seven percent of patients with CD and myelosuppression during azathioprine therapy had mutant alleles of the TPMT gene associated with enzyme deficiency, which is more often caused by other factors than other factors.
632
Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial
P. Marteau,Marc Lémann,P. Seksik,D. Laharie,J.-F. Colombel,Yoram Bouhnik,Guillaume Cadiot,Soulé Jc,Arnaud Bourreille,Etienne Henry Metman,Eric Lerebours,F. Carbonnel,J.L. Dupas,Michel Veyrac,Benoit Coffin,J. Moreau,V. Abitbol,S. Blum-Sperisen,Jean-Yves Mary +18 more
TL;DR: The probiotic strain L johnsonii LA1 (4×109 cfu/day) did not have a sufficient effect, if any, to prevent endoscopic recurrence of Crohn’s disease.
A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine.
Marc Lémann,Jean-Yves Mary,Jean-Frederic Colombel,Bernard Duclos,Soulé Jc,Eric Lerebours,Robert Modigliani,Yoram Bouhnik +7 more
TL;DR: This study shows that azathioprine withdrawal is not equivalent to continued therapy with azathyprine for maintenance of remission in patients with Crohn's disease who have been in remission on azithioprine for > or = 3.5 years.
365
Identification of Restricted Subsets of Mature microRNA Abnormally Expressed in Inactive Colonic Mucosa of Patients with Inflammatory Bowel Disease
Magali Fasseu,Xavier Treton,Xavier Treton,Cécile Guichard,Cécile Guichard,Eric Pedruzzi,Eric Pedruzzi,Dominique Cazals-Hatem,Dominique Cazals-Hatem,Christophe Richard,Christophe Richard,Thomas Aparicio,Thomas Aparicio,Fanny Daniel,Fanny Daniel,Soulé Jc,Soulé Jc,Richard Moreau,Richard Moreau,Yoram Bouhnik,Yoram Bouhnik,Marc Laburthe,Marc Laburthe,André Groyer,André Groyer,Eric Ogier-Denis,Eric Ogier-Denis +26 more
TL;DR: This study supports miRNAs as crucial players in the onset and/or relapse of inflammation from quiescent mucosal tissues in IBD patients and suggests that some of the miRNA with altered expression in the quiescence mucosa of I BD patients may define miRNA signatures for UC and CD and help develop new diagnostic biomarkers.
297
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Robert Modigliani,J.-F. Colombel,J.L. Dupas,M. Dapoigny,V Costil,Michel Veyrac,Bernard Duclos,Soulé Jc,Jean-Pierre Gendre,Jean-Paul Galmiche,O. Danne,Guillaume Cadiot,Hervé Lamouliatte,Jacques Belaiche,Jean-Yves Mary +14 more
TL;DR: After a prednisolone-induces remission in Crohn's disease, mesalamine facilitates steroid withdrawal and, during the postweaning year, may reduce the relapse rate in certain patient subgroups.
151